ISTA Pharmaceuticals says FDA to review once-daily eye inflammation treatment by Oct. 16

ISTA says FDA to review eye drug by Oct. 16

IRVINE, Calif. — ISTA Pharmaceuticals Inc. said Monday the Food and Drug Administration will make a regulatory decision on the once-daily eye inflammation treatment XiDay by Oct. 16.

The drug is a once-per-day version of Xibrom, a drug that is already on the market but is intended to be used twice a day.

XiDay, like Xibrom, is aimed at treating eye inflammation following cataract surgery.

ISTA said the FDA is still considering the company’s request for a shorter, six-month, priority review.

ISTA reported Xibrom net sales of $81.1 million for the year ended December 31, 2009.

Shares of ISTA rose 6 cents to $3.89 in after-hours trading after rising 10 cents, or 2.7 percent, to close at $3.83 during the regular trading session.